Navigation Links
Australian Biotech Ceridia Pty Ltd Completes Successful Human Clinical Trial
Date:7/26/2011

ADELAIDE, Australia, July 26, 2011 /PRNewswire/ -- Ceridia Pty Ltd., a biotechnology company focused on reformulating and developing therapeutic drugs, announce the successful completion of Phase 1 Proof-of-Concept study of its novel LipoCeramic ibuprofen formulation, CER006.  CER006 was designed to be a model formulation to establish safety and tolerability of Ceridia's LipoCeramic reformulation technology but also to attain pharmacokinetic information in humans.

Trial demonstrates that the technology is safe and well tolerated. Study also suggests fast and improved delivery of ibuprofen when comparing with branded market leader.

Based on the safety and pharmacokinetics data from this 4-arm blinded study, Ceridia plans to commence a number of bio-equivalence and bioavailability trials which will include anti-inflammatory, anti-infective and oncology drugs.

"We are very pleased to demonstrate that Ceridia's LipoCeramic platform technology is safe and well tolerated in humans.  It is a clinical validation of more than 10 years of research and development," said Dr Gregor Rozenberg, Ph.D., CEO, Ceridia. "We are now poised to initiate a number of Phase 2 studies with the aim of reformulating and improving the clinical profiles of several therapeutic drugs.  Commercialisation can now be accelerated."

Ceridia Pty Ltd is supported by ITEK, the intellectual property commercialisation arm of UniSA and has entered into collaborations with Pharma and Biotech using its innovative reformulation technology to improve existing and novel drugs. The company is seeking additional investment and partnerships.

Reformulating approved drugs enables reprofiling or repurposing of therapeutic agents. This in turn provides new commercial opportunities in an abbreviated regulatory environment. This reduces development times significantly and produces better drugs quicker and cheaper.

Ceridia

Ceridia is a privately owned spin-out company of the University of South Australia.  Ceridia is commercializing a novel method of reformulating oil-soluble compounds.  A silica-lipid nano-encapsulation platform technology has been developed and protected by patents worldwide.  This technology enables the pharmaceutical and biotechnology industry to improve efficacy, bio-availability and stability of drugs and help reduce their time to market.  The technology is clinically proven to be completely safe, uses no synthetic, toxic or corrosive solvents. The manufacturing process is straightforward and can be quickly transferred into most API manufacturing sites and requires no additional capital expenditure.  Human clinical trials indicate improved clinical profile and quicker drug uptake.

Contact:
Gregor Rozenberg, CEO
Email: gregor@ceridia.com.au
Website: www.ceridia.com.au


'/>"/>
SOURCE Ceridia Pty Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Australian Center Readies Brain Research Program for Addition of Elekta MEG System
2. Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
3. OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction
4. New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
5. New Australian Technology: Detecting Breast Cancer With Hair
6. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
7. Top 5 Ways to Get Insider Track on Healthcare, Pharma & Biotech Discoveries & Latest News
8. Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
9. 2011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent
10. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
11. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
(Date:6/24/2016)... ... 2016 , ... To succeed under value-based payments, healthcare providers ... how to move forward, given the need to sustain current operations. PYA has ... an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers want ...
(Date:6/24/2016)... ... 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to ... vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The ...
(Date:6/23/2016)... ... June 23, 2016 , ... An article published June 8 ... between head and neck cancer in individuals with unhealthy oral hygiene habits. The article ... on whether they had gum disease, brushed their teeth on a daily basis, wore ...
Breaking Medicine News(10 mins):